查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1684545

數位生物標記市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

Digital Biomarkers Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 142 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年全球數位生物標記市場規模達到 38 億美元，預計 2025 年至 2034 年期間將以 28.8% 的複合年成長率大幅擴張。數位生物標記是反映個人生理、行為或環境狀況的客觀、可測量資料。它們透過穿戴式裝置、行動應用程式和感測器等先進的數位工具收集，為現實環境中的個人健康狀況、疾病進展和治療反應提供重要見解。隨著醫療保健越來越依賴數據，數位生物標記正在改變病情的監測、檢測和管理方式。這些技術不僅提供可檢測健康狀況細微變化的即時資料，而且還為主動的醫療保健策略鋪平了道路，有可能徹底改變預防性護理。透過持續監測健康指標，數位生物標記正在改變疾病管理的格局並幫助臨床醫生做出更明智的決策。

數位生物標記市場 - IMG1

市場分為穿戴式裝置、行動應用程式、感測器和其他數位工具。穿戴式裝置目前佔據市場主導地位，到 2024 年將佔據 42.5% 的佔有率。穿戴式裝置的功能特別強大，因為它們可以持續、即時追蹤關鍵的生理和行為指標，例如心率、睡眠模式、身體活動和血糖水平。與傳統的臨床評估不同，穿戴式裝置能夠全天候追蹤這些指標，提供更詳細的見解，並能夠檢測到可能預示疾病發作的細微健康狀況變化。這種持續監測不僅可以提高早期發現的能力，還可以實現及時的醫療干預，最終改善患者的治療效果。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 38億美元
預測值 462億美元
複合年成長率 28.8％

當考慮臨床實踐時，數位生物標記分為診斷、監測、預測和預後類別。監測生物標記領域在 2024 年佔據 45.8% 的市場佔有率，佔據市場主導地位，並有望實現大幅成長，預計到 2034 年將達到 214 億美元。監測生物標記對於檢測疾病的早期跡象至關重要，尤其是糖尿病和阿茲海默症等慢性病。它們可以檢測出個人健康狀況的細微變化，從而採取更有效、更及時的干涉措施。隨著主動健康管理的需求不斷增加，數位生物標記在監測病情方面的作用將持續成長，從而提高醫療保健的整體有效性。

由於美國強大的技術基礎設施和強大的創新生態系統，美國數位生物標記市場規模到 2034 年預計將達到 165 億美元。人工智慧、機器學習和雲端運算領域大型科技公司的出現加速了先進數位生物標記的發展。此外，健身追蹤器和連續血糖監測儀等穿戴式裝置的廣泛應用在數位生物標記的日益普及中發揮了重要作用。消費者對這些技術的需求持續推動市場擴張，進一步推動這項變革性醫療保健領域的進步。

目錄

第 1 章：方法論與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業衝擊力
    • 成長動力
      • 慢性病盛行率上升
      • 人工智慧和機器學習的進步
      • 穿戴式裝置的普及
      • 遠端監控日益受到關注
    • 產業陷阱與挑戰
      • 先進設備成本高昂
      • 缺乏熟練的專業人員
  • 成長潛力分析
  • 監管格局
  • 技術格局
  • 未來市場趨勢
  • 波特的分析
  • PESTEL 分析

第4章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 策略儀表板

第 5 章：市場估計與預測：按類型，2021 年至 2034 年

  • 主要趨勢
  • 穿戴
  • 基於行動的應用程式
  • 感應器
  • 其他類型

第 6 章：市場估計與預測：按臨床實踐，2021 – 2034 年

  • 主要趨勢
  • 診斷數位生物標記
  • 監測數位生物標記
  • 預測和預後數位生物標記物
  • 其他臨床實踐

第 7 章：市場估計與預測：按治療領域，2021 年至 2034 年

  • 主要趨勢
  • 心血管和代謝疾病（CVMD）
  • 糖尿病
  • 呼吸系統疾病
  • 精神疾病
  • 睡眠和運動疾病
  • 神經系統疾病
  • 肌肉骨骼疾病
  • 其他治療領域

第 8 章：市場估計與預測：依最終用途，2021 年至 2034 年

  • 主要趨勢
  • 醫療保健提供者
  • 付款人
  • 製藥和生物技術公司
  • 學術及研究機構

第 9 章：市場估計與預測：按地區，2021 年至 2034 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第10章：公司簡介

  • ActiGraph
  • AliveCor
  • Altoida
  • Amgen Inc.
  • Adherium Limited
  • Aural Analytic
  • Brainomix
  • Biogen
  • Clario
  • Empatica Inc.
  • Evidation Health Inc.
  • IXICO plc
  • Koneksa
  • Sonde Health, Inc.
  • Vivo Sense
簡介目錄
Product Code: 12954

The Global Digital Biomarkers Market reached USD 3.8 billion in 2024 and is expected to expand significantly at a CAGR of 28.8% between 2025 and 2034. Digital biomarkers are objective, measurable data that reflect an individual's physiological, behavioral, or environmental condition. They are collected through advanced digital tools such as wearables, mobile applications, and sensors, offering crucial insights into a person's health status, disease progression, and treatment responses in real-world settings. As healthcare becomes increasingly data-driven, digital biomarkers are transforming how conditions are monitored, detected, and managed. These technologies not only provide real-time data that can detect subtle changes in health but also pave the way for proactive healthcare strategies, offering the potential to revolutionize preventative care. By enabling continuous monitoring of health indicators, digital biomarkers are changing the landscape of disease management and helping clinicians make more informed decisions.

Digital Biomarkers Market - IMG1

The market is segmented into wearables, mobile applications, sensors, and other digital tools. The wearable segment currently dominates the market, holding a 42.5% share in 2024. Wearables are particularly powerful as they allow for continuous, real-time tracking of key physiological and behavioral indicators, such as heart rate, sleep patterns, physical activity, and glucose levels. Unlike traditional clinical assessments, wearables offer the ability to track these indicators around the clock, providing more detailed insights and the ability to detect even minor changes in health that could signal the onset of disease. This continuous monitoring not only enhances early detection but also enables timely medical intervention, ultimately improving patient outcomes.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$3.8 Billion
Forecast Value$46.2 Billion
CAGR28.8%

When considering clinical practices, digital biomarkers are classified into diagnostic, monitoring, predictive, and prognostic categories. The monitoring biomarkers segment led the market with a 45.8% share in 2024 and is poised for substantial growth, expected to reach USD 21.4 billion by 2034. Monitoring biomarkers are crucial for detecting early signs of diseases, especially chronic conditions like diabetes and Alzheimer's disease. They can detect subtle changes in an individual's health, enabling more effective and timely interventions. As the demand for proactive health management increases, the role of digital biomarkers in monitoring conditions will continue to grow, enhancing the overall effectiveness of healthcare.

The U.S. digital biomarkers market is set to reach USD 16.5 billion by 2034, driven by the country's robust technological infrastructure and a strong innovation ecosystem. The presence of major tech companies in artificial intelligence, machine learning, and cloud computing has accelerated the development of advanced digital biomarkers. In addition, the widespread adoption of wearable devices, such as fitness trackers and continuous glucose monitors, has played a significant role in the growing popularity of digital biomarkers. Consumer demand for these technologies continues to drive market expansion, further fueling advancements in this transformative healthcare sector.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of chronic diseases
      • 3.2.1.2 Advancements in AI and Machine learning
      • 3.2.1.3 Adoption of wearable devices
      • 3.2.1.4 Growing focus on remote monitoring
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High costs of advanced devices
      • 3.2.2.2 Lack of skilled professionals
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Future market trends
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Wearable
  • 5.3 Mobile based applications
  • 5.4 Sensors
  • 5.5 Others types

Chapter 6 Market Estimates and Forecast, By Clinical Practice, 2021 – 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Diagnostic digital biomarkers
  • 6.3 Monitoring digital biomarkers
  • 6.4 Predictive and prognostic digital biomarkers
  • 6.5 Other clinical practices

Chapter 7 Market Estimates and Forecast, By Therapeutic Area, 2021 – 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Cardiovascular and metabolic disorders (CVMD)
  • 7.3 Diabetes
  • 7.4 Respiratory disorders
  • 7.5 Psychiatric disorders
  • 7.6 Sleep and movement diseases
  • 7.7 Neurological disorders
  • 7.8 Musculoskeletal disorders
  • 7.9 Other therapeutic areas

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Healthcare providers
  • 8.3 Payers
  • 8.4 Pharmaceutical and biotechnology companies
  • 8.5 Academic and research institutions

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 ActiGraph
  • 10.2 AliveCor
  • 10.3 Altoida
  • 10.4 Amgen Inc.
  • 10.5 Adherium Limited
  • 10.6 Aural Analytic
  • 10.7 Brainomix
  • 10.8 Biogen
  • 10.9 Clario
  • 10.10 Empatica Inc.
  • 10.11 Evidation Health Inc.
  • 10.12 IXICO plc
  • 10.13 Koneksa
  • 10.14 Sonde Health, Inc.
  • 10.15 Vivo Sense